US-based Ionis Pharmaceuticals’ affiliate Akcea Therapeutics has launched a Phase II clinical programme of AKCEA-ANGPTL3-L to treat rare hyperlipidemias.

AKCEA-ANGPTL3-L ­is being developed to minimise the production of angiopoietin-like 3 (ANGPTL3) for cardioprotective effect and decreased risk of insulin resistance and diabetes mellitus.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Phase II programme will include three clinical trials for familial chylomicronemia syndrome (FCS), familial partial lipodystrophy (FPL), and homozygous familial hypercholesterolemia (HoFH).

In addition to evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics, the trials will aim to characterise the potential of AKCEA-ANGPTL3-L in specific patient populations.

“We are committed to developing additional therapeutic options for these patient populations whose significant medical needs are currently greatly underserved.”

Akcea Therapeutics chief medical officer Louis O’Dea said: “ANGPTL3 is a key regulator of a number of lipid and metabolic pathways and as such is an important target for the therapeutic management of rare hyperlipidemias, such as FCS, FPL, and HoFH.

“We are committed to developing additional therapeutic options for these patient populations whose significant medical needs are currently greatly underserved.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The first trial under the programme will include an assessment of subcutaneous, once weekly injection of AKCEA-ANGPTL3-L over a period of 13 weeks in subjects with FCS.

Scheduled to report top-line results next year, this trial will be followed by studies in FPL and HoFH patients.

AKCEA-ANGPTL3-L was found to be well-tolerated during a Phase I/II clinical trial conducted in subjects with increased triglycerides, with an 85% dose-dependent decrease in ANGPTL3 protein after six weeks.

Performed for various doses of the drug candidate, the trial further showed similar reductions in triglycerides; low-density lipoprotein (LDL), very low-density lipoprotein (VLDL), and non-high desnsity lipoprotein (HDL) cholesterol; apolipoprotein B; and apolipoprotein C-III protein.